Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Garon EB, et al. Among authors: cappuzzo f. Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2. Lancet. 2014. PMID: 24933332 Clinical Trial.
Gemcitabine in non-small cell lung cancer.
Crinò L, Cappuzzo F. Crinò L, et al. Among authors: cappuzzo f. Expert Opin Pharmacother. 2002 Jun;3(6):745-53. doi: 10.1517/14656566.3.6.745. Expert Opin Pharmacother. 2002. PMID: 12036414 Review.
Role of gemcitabine in cancer therapy.
Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Toschi L, et al. Among authors: cappuzzo f. Future Oncol. 2005 Feb;1(1):7-17. doi: 10.1517/14796694.1.1.7. Future Oncol. 2005. PMID: 16555971 Review.
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M. Crinò L, et al. Among authors: cappuzzo f. J Clin Oncol. 2008 Sep 10;26(26):4253-60. doi: 10.1200/JCO.2007.15.0672. J Clin Oncol. 2008. PMID: 18779612 Clinical Trial.
Emerging drugs for small-cell lung cancer.
Metro G, Cappuzzo F. Metro G, et al. Among authors: cappuzzo f. Expert Opin Emerg Drugs. 2009 Dec;14(4):591-606. doi: 10.1517/14728210903206983. Expert Opin Emerg Drugs. 2009. PMID: 19694501 Review.
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Cappuzzo F, et al. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20. Lancet Oncol. 2010. PMID: 20493771 Clinical Trial.
Consequences of targeted treatments for second-line therapy.
De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, Cappuzzo F. De Maio E, et al. Among authors: cappuzzo f. Ann Oncol. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. Ann Oncol. 2010. PMID: 20943621 Free article. Review.
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.
Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, Gopalakrishna P, Cappuzzo F; SATURN Investigators. Coudert B, et al. Among authors: cappuzzo f. Ann Oncol. 2012 Feb;23(2):388-94. doi: 10.1093/annonc/mdr125. Epub 2011 May 24. Ann Oncol. 2012. PMID: 21610154 Free article. Clinical Trial.
310 results